Abstract
BH4 therapy is an advancement in the treatment of phenylketonuria, reducing blood phenylalanine (phe) levels and increasing tolerance to natural proteins of responding patients. We report the results of 16 patients undergoing long-term BH4 treatment. Responding patients to BH4 was usually based on 24-h loading tests; a ≥30% decrease in blood phe was considered a positive response. Weekly loading made it possible to identify an additional “slow responder.” The 16 responders constitute 24.6% of patients who completed the trial (87.5% of responders in mild hyperphenylalaninemia, 38.1% in mild PKU, and 2.8% in classical PKU).
Mean dose of BH4 used was 9.75 ± 0.9 mg/kg per day, during a mean of 62 months. Age at treatment start was below 4 years in seven patients; five of which begun treatment during their first month since birth. All but one patient showed good treatment compliance; six continue on BH4 monotherapy without dietary phe restriction; six showed an increase in phe tolerance of 24–55%; and in the five patients who received treatment since the neonatal period an increase in phe tolerance following the phase of maximum growth has persisted. None of the patients showed side effects except one whom vomiting at the beginning of the treatment.
Testing at the time of diagnosis in the neonatal period is very appropriate, and if there is a positive response, the patient can be treated with BH4 from onset with the advantage of being able to continue breast-feeding.
Competing interests: None declared.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Acosta PB, Yannicelli S (1999) Plasma micronutrient concentrations in infants undergoing for pheylketonuria. Biol Trace Elem Res 67:75–84
Belanger-Quintana A, García MJ, Castro M et al (2005) Spanish BH4-responsive phenylalanine hydroxylase-deficient patients: evolution of seven patients on long-term treatment with tetrahydrobiopterin. Mol Genet Metab 86:S61–S66
Blau N (2008) Defining tetrahydrobiopterin (BH4)-responsiveness in PKU. J Inherit Metab Dis 31:2–3
Blau N, Bélanger-Quintana A, Demirkol M et al (2009) Optimizing the use of sapropterin (BH4) in the management of phenylketonuria. Mol Genet Metab 96:158–163
Blau N, Bélanger-Quintana A, Dermikol M et al (2010) Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab 99:109–115
Bóveda MD, Couce ML, Castiñeiras DE et al (2007) The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninaemia: evaluation of response and subsequent treatment. J Inherit Metab Dis 30(5):812
Burlina A, Blau N (2009) Effect of BH4 supplementation on phenylalanine tolerance. J Inherit Metab Dis 32:40–45
Burnett JR (2007) Sapropterin dihydrochloride (Kuvan/Phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria. I Drugs 10:805–813
Burton BK, Adams DJ, Grange DK et al (2011) Tetrahydrobiopterin therapy for Phenylketonuria in infants and young children. J Pediatr 158:410–415
Daniele A, Scala I, Cardillo G et al (2009) Functional and structural characterization of novel mutations and genotype-phenotype correlation in 51 phenylalanine hydroxylase deficient families from Southern Italy. FEBS J 276:2048–2059
Desviat L, Pérez B, Bélanger-Quintana A et al (2004) Tetrahydrobiopterin responsiveness results of the BH4 loading test in 31 Spanish PKU patients and correlation with their genotype. Mol Genet Metab 83:157–162
Feillet F, Chery C, Namour F et al (2008) Evaluation of neonatal BH4 loading test in neonatae screened for hyperphenylalaninemia. Early Hum Dev 84:561–567
Gersting SW, Lagler FB, Eichinger A et al (2010) Pahenu 1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. Hum Mol Genet 19:2039–2049
Hennermann JB, Bührer C, Blau N, Vetter B, Mönch E (2005) Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol Genet Metab 86:S86–S90
Kure S, Hou DC, Ohura T et al (1999) Tetrahydrobiopterin responsive phenylalanine hydroxylase deficiency. J Pediatr 135(3):375–378
Kuvan® (2008) US Prescribing Information. Available at www.kuvan.com. (accesed August 2008)
Nielsen JB, Nielsen KE, Güttler F (2010) Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation. J Inherit Metab Dis 33:9–16
Shintaku H, Kure S, Ohura T et al (2004) Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene. Pediatr Res 55:425–430
Spaapen LJM, Bakker JA, Velter c et al (2001) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency in Dutch neonatos. J Inherit Metab Dis 24:352–358
Trefz FK, Burton BK, Longo N et al (2009a) Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr 154:700–707
Trefz FK, Scheible D, Gotz H, Frauendienst-Egger G (2009b) Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria. J Inherit Metab Dis 32:22–26
Trefz FK, Scheible D, Frauendienst-Egger G (2010) Long-term follow-up of patients with phenylketonuria receiving tetrahydrobiopterin treatment. J Inherit Metab Dis Mar 9. (Epub ahead of print)
Vernon HJ, Koerner CB, Johnson MR, Bergner A, Hamosh A (2010) Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria. Mol Genet Metab 100:229–233
Wang L, Surendran S, Michals-Matalon K et al (2007) Mutations in the regulatory domain of phenylalanine hydroxylase and response to tetrahydrobiopterin. Genet Test 11:174–178
Zurflüh MR, Zschozke J, Lindner M et al (2008) Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum Mutat 29:67–75
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Nenad Blau.
Synopsis
Synopsis
This study presents long-term evolution of 16 PKU patients undergoing BH4 treatment showing its efficacy. Furthermore, it highlights the usefulness of BH4 test at the time of diagnosis in the neonatal period and the early treatment if there is a positive response.
Rights and permissions
Copyright information
© 2011 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Couce, M.L., Bóveda, M.D., Valerio, E., Pérez-Muñuzuri, A., Fraga, J.M. (2011). Long-Term Pharmacological Management of Phenylketonuria, Including Patients Below the Age of 4 Years. In: JIMD Reports - Case and Research Reports, 2011/2. JIMD Reports, vol 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2011_53
Download citation
DOI: https://doi.org/10.1007/8904_2011_53
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-24757-6
Online ISBN: 978-3-642-24758-3
eBook Packages: MedicineMedicine (R0)